Cardiology
Conference Coverage
Benefit of rivaroxaban after limb revascularization greatest in those with comorbid CAD
New results from the landmark VOYAGER PAD trial identify which patients benefit most from adding rivaroxaban after limb revascularization.
Applied Evidence
Choosing Wisely: 10 practices to stop—or adopt—to reduce overuse in health care
The evidence-based recommendations presented here, made by the AAFP and other societies, can help you to avoid unnecessary testing and...
From the Journals
The socioeconomic revolving door of 30-day heart failure readmissions
Racial disparities in 30-day HF readmissions stem partly from variation in economic status of residential neighborhoods, regardless of hospital...
Feature
Surgeon general pushes for improved hypertension control
“We cannot wait to deal with this epidemic of uncontrolled high blood pressure” that affects more than 82 million American, U.S. Surgeon General...
Conference Coverage
Teen affective disorders raise risk for midlife acute MI
“Effective prevention might focus on behavior, lifestyle, and psychosocial stress in early life,” said Dr. Cecilia Bergh.
From the Journals
MI recurrences drop, but women underestimate disease risk
Women show greater reductions in recurrent heart attacks and heart disease compared with men, but survey reveals reduced awareness of mortality...
From the Journals
Time-restricted eating shows no weight-loss benefit in RCT
Those randomized to eating only between noon and 8 p.m. showed no greater weight loss versus a control group, while a large proportion of weight...
From the Journals
Psychosocial resilience associated with better cardiovascular health in Blacks
Psychosocial resilience has the potential to explain variability in cardiovascular risk among Black patients.
Conference Coverage
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
Conference Coverage
Music’s charms may soothe heart failure’s effects
Evidence builds that music, either heard or sung, exerts measurable benefits for heart failure and other cardiovascular diseases.
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...